Merck & Co. Inc. shares inched 0.92% higher to $75.87 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.14% to 4,208.12 and the Dow Jones Industrial Average DJIA rising 0.07% to 34,600.38.
Merck & Co. Inc. closed $11.93 short of its 52-week high ($87.80), which the company achieved on September 3rd. The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson JNJ rose 0.40% to $166.20, Roche Holding AG Part. Cert. RHHVF rose 1.90% to $345.52, and Pfizer Inc. PFE rose 0.75% to $38.79.
The company will also go beyond offering products forcontraception and fertility in a bid to ‘broaden its definition of women’s health’, to address conditions that either is unique to women or that disproportionately affect them. The pharmaceuticals outside the US and Canada envisions that Organon will be sitting within an addressable market of more than $60m by 2026. The company’s chief financial officer Caroline Litchfield added that, upon close of the Organon spinoff, the company is expecting to receive a tax-free dividend of $9bn.